Prostate cancer in the elderly

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 6, 2009, Pages 668-672

  Heinzer, Hans ^a   Steuber, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Comorbidity; Hormone therapy; Prostate cancer; Radical prostatectomy; Radiotherapy; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; COMORBIDITY; CRYOSURGERY; GERIATRIC CARE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT PLANNING; ULTRASOUND THERAPY;

AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; GERIATRIC ASSESSMENT; HUMANS; MALE; MASS SCREENING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 70350499261     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.07.015     Document Type: Review

References (50)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics. CA Cancer J Clin 55 (2002) 74-108
2. American Cancer Society. Cancer Facts and Figures. www.cancer.org Accessed August 2009
3. Surveillance Epidemiology and End Results (SEER). SEER data for 2000-2004. www.cancer.gov Accessed April 2008
4. Sirovich B.E., Schwartz L.M., and Woloshin S. Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence?. JAMA 289 (2003) 1414-1420
5. Yabroff K.R., Lamont E.B., Mariotto A., et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100 (2008) 630-641
6. Bartsch G., Horninger W., Klocker H., et al., Tyrol Prostate Cancer Screening Group. Tyrol Prostate Cancer Demonstration Project: Early detection, treatment, outcome, incidence and mortality. BJU Int 101 (2008) 809-816
7. Andriole G.L., Levin D.L., Crawford E.D., et al., PLCO Project Team. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97 (2005) 433-438
8. de Vries S.H., Postma R., Raaijmakers R., et al. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol 51 (2007) 366-374
9. American Urological Association (AUA). Prostate-specific antigen (PSA) Best Practice Policy. Oncology 14 (2000) 267-280
10. Smith R.A., Cokkinides V., and Brawley O.W. Cancer screening in the United States, 2008: A review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin 58 (2008) 161-179
11. Lu-Yao G., Stukel T.A., and Yao S.L. Prostate-specific antigen screening in elderly men. J Natl Cancer Inst 95 (2003) 1792-1797
12. Walter L.C., Bertenthal D., Lindquist K., et al. PSA screening among elderly men with limited life expectancies. JAMA 296 (2006) 2336-2342
13. Konety B.R., Sharp V.J., Raut H., et al. Screening and management of prostate cancer in elderly men: The Iowa Prostate Cancer Consensus. Urology 71 (2008) 511-514
14. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163-2172
15. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
16. Klotz L. Active surveillance for favorable risk prostate cancer: Rationale, risks, and results. Urol Oncol 25 (2007) 505-509
17. Albertsen P.C., Hanley J.A., Gleason D.F., et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280 (1998) 975-980
18. Sweat S.D., Bergstralh E.J., Slezak J., et al. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 168 (2002) 525-529
19. Aus G., Abbou C.C., Bolla M., et al., European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
20. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3 Suppl 1 (2005) 29-33
21. Albertsen P.C., Fryback D.G., Storer B.E., et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156 (1996) 127-132
22. Cowen M.E., Halasyamani L.K., and Kattan M.W. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 175 (2006) 99-103
23. Tewari A., Johnson C.C., Divine G., et al. Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment, and comorbidities. J Urol 171 (2004) 1513-1519
24. Walz J., Gallina A., Perrotte P., et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 100 (2007) 1254-1258
25. Walz J., Suardi N., Shariat S.F., et al. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int 102 (2008) 33-38
26. Walz J., Gallina A., Saad F., et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 25 (2007) 3576-3581
27. Fitzpatrick J.M. Management of localized prostate cancer in senior adults: The crucial role of comorbidity. BJU Int 101 Suppl 2 (2008) 16-22
28. Bubolz T., Wasson J.H., Lu-Yao G., et al. Treatments for prostate cancer in older men: 1984-1997. Urology 58 (2001) 977-982
29. Houterman S., Janssen-Heijnen M.L., Verheij C.D., et al. Greater influence of age than comorbidity on primary treatment and complications of prostate cancer patients: An in-depth population-based study. Prostate Cancer Prostatic Dis 9 (2006) 179-184
30. Schwartz K.L., Alibhai S.M., Tomlinson G., et al. Continued undertreatment of older men with localized prostate cancer. Urology 62 (2003) 860-865
31. Konety B.R., Cowan J.E., Carroll P.R., and CaPSURE Investigators. Patterns of primary and secondary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE. J Urol 179 (2008) 1797-1803
32. Damber J.E., and Aus G. Prostate cancer. Lancet 371 (2008) 1710-1721
33. Harlan S.R., Cooperberg M.R., Elkin E.P., et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 170 (2003) 1804-1807
34. Bill-Axelson A., Holmberg L., Ruutu M., et al. Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy vs. watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
35. Wong Y.N., Mitra N., Hudes G., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296 (2006) 2683-2693
36. Siddiqui S.A., Sengupta S., Slezak J.M., et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 175 (2006) 952-957
37. Loeb S., Hernandez D.J., Mangold L.A., et al. Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int 101 (2008) 1503-1506
38. Jeldres C., Suardi N., Walz J., et al. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: A population-based study of 6183 men. Eur Urol 54 (2008) 107-117
39. Begg C.B., Riedel E.R., Bach P.B., et al. Variations in morbidity after radical prostatectomy. N Engl J Med 346 (2002) 1138-1144
40. Alibhai S.M., Leach M., Tomlinson G., et al. Thirty-day mortality and major complications after radical prostatectomy: Influence of age and comorbidity. J Natl Cancer Inst 97 (2005) 1525-1532
41. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360 (2002) 103-106
42. Johnstone P.A., Riffenburgh R.H., Moul J.W., et al., Department of Defense Center for Prostate Disease Research. Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: A radiation oncology report of the Department of Defense Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys 55 (2003) 964-969
43. Jani A.B., Parikh S.D., Vijayakumar S., et al. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology 65 (2005) 1157-1162
44. Chen A.B., D'Amico A.V., Neville B.A., et al. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 24 (2006) 5298-5304
45. Aus G. Current status of HIFU and cryotherapy in prostate cancer: A review. Eur Urol 50 (2006) 927-934
46. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
47. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
48. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
49. Shahinian V.B., Kuo Y.F., and Freeman J.L. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
50. Abrahamsen B., Nielsen M.F., Eskildsen P., et al. Fracture risk in Danish men with prostate cancer: A nationwide register study. BJU Int 100 (2007) 749-754